Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03074513 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors

StatusActive, Not Recruiting
PhasePhase 2
Started2017-03-03
View on ClinicalTrials.gov ↗
This phase II trial studies how well atezolizumab and bevacizumab work in treating patients with rare solid tumors. Immunotherapy with monoclonal antibodies, such as atezolizumab and bevacizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.

Amendment record

Amended 50 times since 2017-03-03; most recent filed 2026-09-10. The 50 most recent of 51 record versions are listed below. See every version on ClinicalTrials.gov ↗

Dates here are the day the sponsor filed the amendment, not the day ClinicalTrials.gov published it. Version history last read from ClinicalTrials.gov on 2026-09-15.

2026-09-10
Amendment Study Status v50
2026-03-10
Amendment Study Status v49
2026-03-03
Amendment Study Status v48
2025-09-08
Amendment Study Status v47
2025-04-24
Amendment Study Identification, Study Status, Oversight, Conditions v46
2024-10-21
Amendment Study Identification, Study Status, Oversight, Conditions v45
2024-10-08
Amendment Study Status v44
2024-08-01
Amendment Study Status v43
2024-07-30
Amendment Study Status, Contacts/Locations v42
2024-05-14
Amendment Study Status v41
2024-04-17
Amendment Study Status v40
2023-10-12
Amendment Study Status, Study Design v39
2023-10-02
Amendment Study Status v38
2023-09-11
Amendment Study Status v37
2023-05-22
Amendment Study Status v36
2022-12-07
Amendment Study Status v35
2022-12-05
Amendment Study Status v34
2022-07-26
Amendment Study Status, Contacts/Locations, References v33
2022-02-25
Amendment Study Identification, Study Status, Study Design v32
2022-01-18
Amendment Study Status v31
2021-02-23
Amendment Study Status v30
2020-07-28
Amendment Recruiting→Active, Not Recruiting Study Status, Study Design, Contacts/Locations v29
2020-06-18
Amendment Study Status v28
2019-06-11
Amendment Study Identification, Study Status, Sponsor/Collaborators, Study Description, Conditions, Study Design, Arms and Interventions, Outcome Measures, Eligibility, Contacts/Locations v27
2019-05-01
Amendment Study Status v26
2019-01-07
Amendment Study Status v25
2018-11-09
Amendment Study Status v24
2018-10-17
Amendment Study Status v23
2018-09-12
Amendment Study Status v22
2018-08-09
Amendment Study Status v21
2018-07-06
Amendment Study Status, Eligibility, Contacts/Locations v20
2018-06-19
Amendment Study Status v19
2018-05-25
Amendment Study Status v18
2018-03-19
Amendment Study Status v17
2018-03-14
Amendment Active, Not Recruiting→Recruiting Study Status, Study Design, Contacts/Locations v16
2018-01-12
Amendment Recruiting→Active, Not Recruiting Study Status, Study Design, Contacts/Locations v15
2018-01-03
Amendment Study Status v14
2017-12-29
Amendment Study Status, Study Description v13
2017-11-27
Amendment Study Status, Eligibility v12
2017-09-08
Amendment Study Status, Study Description v11
2017-08-23
Amendment Study Status v10
2017-08-22
Amendment Study Status, Eligibility v9
2017-07-07
Amendment Study Status, Eligibility v8
2017-05-26
Amendment Study Status, Study Description, Eligibility v7
2017-05-25
Amendment Study Status v6
2017-05-04
Amendment Study Status v5
2017-04-19
Amendment Study Status, Contacts/Locations v4
2017-04-05
Amendment Study Status, Study Description v3
2017-03-24
Amendment Study Identification, Study Status v2
2017-03-08
Amendment Study Status, Study Description, Eligibility, Contacts/Locations v1
Trial Details
NCT Number NCT03074513
Lead Sponsor M.D. Anderson Cancer Center
Collaborators: National Cancer Institute (NCI)
Conditions Appendix Adenocarcinoma, Human Papillomavirus-Related Anal Squamous Cell Carcinoma, Human Papillomavirus-Related Cervical Squamous Cell Carcinoma, Human Papillomavirus-Related Squamous Cell Carcinoma of the Penis, Human Papillomavirus-Related Vulvar Squamous Cell Carcinoma, Neuroendocrine Carcinoma, Pancreatic Neuroendocrine Tumor, Recurrent Merkel Cell Carcinoma +13 more
Enrollment 133 participants
Start Date 2017-03-03
Primary Completion 2027-09-30 (estimated)
Study Completion 2027-09-30 (estimated)
Updated on ClinicalTrials.gov 2026-09-14